Side-chain-modified analogs of calcitriol cause resistance of human HL-60 promyelocytic leukemia cells to drug-induced apoptosis

Steroids

Volumn 70, Issue 1, 2005, Pages 19-27

  Chrobak, Agnieszka ^a   Radzikowski, Czesław ^a   Opolski, Adam ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Calcitriol and its analogs; Cisplatin; Doxorubicin; Etoposide; Genistein; HL 60 cells; Resistance to apoptosis; Steroid; Taxol

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITRIOL DERIVATIVE; CISPLATIN; COLECALCIFEROL DERIVATIVE; CYTOSTATIC AGENT; DNA FRAGMENT; DOXORUBICIN; ETOPOSIDE; GENISTEIN; PACLITAXEL; PRI 1906; PRI 2191; UNCLASSIFIED DRUG;

AGAR GEL ELECTROPHORESIS; APOPTOSIS; ARTICLE; CELL CYCLE; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; INCUBATION TIME; STATISTICAL SIGNIFICANCE;

APOPTOSIS; CALCITRIOL; CELL CYCLE; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE;

EID: 11144334613     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2004.08.004     Document Type: Article

References (42)

1. D. Feldman, P.J. Malloy, and C. Gross Vitamin D: metabolism and action R. Marcus D. Feldman J. Kelsey Osteoporosis 1996 Academic Press San Diego
2. 3 J Steroid Biochem Mol Biol 67 1998 71 78
3. A. Opolski, J. Wietrzyk, A. Chrobak, E. Marcinkowska, E. Wojdat, and A. Kutner Antiproliferative activity in vitro of side-chain analogues of calcitriol against various human normal and cancer cell lines Anticancer Res 19 1999 5217 5222
4. 3 and clinical applications Bone 17 Suppl. 1995 107S 111S
5. 3 function as ligands for the D-binding protein, nuclear receptor and membrane receptor: a status report J Steroid Biochem Mol Biol 56 Spec no. 1996 13 22
6. D.J. Mangelsdorf, C. Thummel, M. Beato, P. Herrlich, G. Schutz, and K. Umesono The nuclear receptor superfamily: the second decade Cell 83 1995 835 839
7. D.D. Bikle Clinical counterpoint: Vitamin D: new actions, new analogs, new therapeutic potential Endocr Rev 13 1992 765 784
8. 3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid Science 206 1979 1188 1190
9. K. Colston, M. Hirt, and D. Feldman Organ distribution of the cytoplasmic 1,25-dihydroxycholecalciferol receptor in various mouse tissues Endocrinology 107 1980 1916 1922
10. 3 receptor in target cells Endocrinology 122 1988 1224 1230
11. U. Berger, P. Wilson, R.A. McClelland, K. Colston, M.R. Haussler, and J.W. Pike Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues J Clin Endocrinol Metab 67 1988 607 613
12. 3 on primary cultures of human prostatic cells Cancer Res 54 1994 805 810
13. H.A. Pols, J.C. Birkenhager, and J.P. van Leeuwen Vitamin D analogues: from molecule to clinical application Clin Endocrinol (Oxf) 40 1994 285 292
14. H.A. Pols, J.C. Birkenhager, J.A. Foekens, and J.P. van Leeuwen Vitamin D: a modulator of cell proliferation and differentiation J Steroid Biochem Mol Biol 37 1990 873 876
15. 3, and granulocyte-macrophage colony-stimulating factor Blood 90 1997 4578 4587
16. 3 analogue KH1060 combined with TPA synergistically induces mature macrophages in human myeloblastic leukemia ML-1 cells Anticancer Res 19 1999 1069 1076
17. 3 of cytotoxicity to HL-60 cells produced by cytarabine and hydroxyurea J Natl Cancer Inst 76 1986 641 648
18. 3 and platinum drugs on the growth of MCF-7 cells Cancer Res 51 1991 2848 2853
19. 3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage Cancer Res 59 1999 862 867
20. R. Bouillon, W.H. Okamura, and A.W. Norman Structure-function relationship in the Vitamin D endocrine system Endocr Rev 16 1995 200 257
21. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia Endocrinology 129 1991 832 837
22. J. Abe-Hashimoto, T. Kikuchi, T. Matsumoto, Y. Nishii, E. Ogata, and K. Ikeda Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen Cancer Res 53 1993 2534 2537
23. 3 on the growth of human keratinocytes J Dermatol 17 1990 97 103
24. A. Opolski, J. Wietrzyk, A. Siwinska, E. Marcinkowska, A. Chrobak, and C. Radzikowski Biological activity in vitro of side-chain modified analogues of calcitriol Curr Pharm Des 6 2000 755 765
25. A. Siwinska, A. Opolski, A. Chrobak, J. Wietrzyk, E. Wojdat, and A. Kutner Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of Vitamin D Anticancer Res 21 2001 1925 1929
26. 3 and retinoic acid Exp Cell Res 249 1999 279 290
27. H. Asou, M. Koike, E. Elstner, M. Cambell, J. Le, and M.R. Uskokovic 19-Nor Vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines Blood 92 1998 2441 2449
28. 3 activate three MAPK pathways and upregulate pRb expression in differentiating HL60 cells Cell Cycle 1 2002 410 415
29. 3 is associated with increased mitochondrial MCL-1 and RAF-1 proteins and reduced release of cytochrome C Exp Cell Res 235 1997 210 217
30. 3 inhibits programmed cell death in HL-60 cells by activation of sphingosine kinase Cancer Res 58 1998 1817 1824
31. G. Del Bino, X. Li, F. Traganos, and Z. Darzynkiewicz Altered susceptibility of differentiating HL-60 cells to apoptosis induced by antitumor drugs Leukemia 8 1994 281 288
32. T.G. Cotter, R.S. Fernandes, S. Verhaegen, and J.V. McCarthy Cell death in the myeloid lineage Immunol Rev 142 1994 93 112
33. E. Solary, R. Bertrand, K.W. Kohn, and Y. Pommier Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors Blood 81 1993 1359 1368
34. L.A. Zwelling, D. Chan, M. Hinds, J. Mayes, L.E. Silberman, and M. Blick Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells Cancer Res 48 1988 6625 6633
35. J.H. Doroshow Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase Cancer Res 43 1983 4543 4551
36. 3-induced monocyte differentiation Cancer Res 50 1990 1183 1188
37. K.L. Donaldson, G.L. Goolsby, and A.F. Wahl Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle Int J Cancer 57 1994 847 855
38. 3 protects human leukemic cells from tumor necrosis factor-induced apoptosis via inactivation of cytosolic phospholipase A2 Cancer Res 58 1998 633 640
39. D. Wolf, and V. Rotter Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells Proc Natl Acad Sci USA 82 1985 790 794
40. E. Marcinkowska, A. Chrobak, and A. Wiȩdłocha Evading apoptosis by calcitriol-differentiated human leukemic HL-60 cells is not mediated by changes in CD95 receptor system but by increased sensitivity of these cells to insulin Exp Cell Res 270 2001 119 127
41. G. Bergh, M. Ehinger, T. Olofsson, B. Baldetorp, E. Johnsson, and H. Brycke Altered expression of the retinoblastoma tumor-suppressor gene in leukemic cell lines inhibits induction of differentiation but not G1-accumulation Blood 89 1997 2938 2950
42. 3 reverses the G1 block but not differentiation of HL60 cells Leukemia 12 1998 1256 1265